Persisting murine cytomegalovirus can reactivate and has unique transcriptional activity in ocular tissue.
Cytomegalovirus (CMV) retinitis is an important ocular complication in human immunodeficiency virus-infected individuals and the leading cause of blindness in those not undergoing highly active antiretroviral therapy. Murine CMV (MCMV) infection of mice has been shown to be a useful small-animal model for the study of CMV pathogenesis in the eye. The purpose of this study was to evaluate CMV persistence in ocular tissue and to determine the potential for reactivation. Following subretinal inoculation of immunocompetent BALB/c mice, tissues were tested for infectious virus by plaque assay and for the presence of viral DNA and RNA by PCR. The latent phase of the infection in mouse tissues was analyzed by plaque assay, PCR, and explantation cocultivation in both immunocompetent and cyclophosphamide-treated mice. The acute phase of the infection was resolved by 2 to 3 weeks postinfection, while viral DNA persisted beyond 12 months. Immediate-early 1 transcripts were detected in 100% of the ocular samples tested, and glycoprotein H transcripts were detected in 86% of the samples, but no difference in viral DNA or RNA levels between immunocompetent and immunosuppressed animals was measured. Irrespective of immune status, no in vivo reactivation was detected; however, reactivated virus was observed in 76 to 82% of the eyes following explantation onto a permissive cell layer. The transcriptional activity and relatively high frequency of explantation-induced reactivation in both immunocompetent and immunosuppressed mice suggest that control of MCMV latency in ocular tissue might involve other regulatory events that are not entirely dependent on intact specific immunity.
Kercher
Lisa
L
Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas 77030, USA.
Mitchell
Bradley M
BM
D000818:Animals; D003520:Cyclophosphamide / Q000494:pharmacology; D004279:DNA, Viral / Q000032:analysis; D015828:Eye Infections, Viral / Q000821:virology*; D006566:Herpesviridae Infections / Q000821:virology*; D017874:Immediate-Early Proteins / Q000378:metabolism; D007121:Immunocompetence; D007165:Immunosuppression Therapy; D051379:Mice; D008807:Mice, Inbred BALB C; D018146:Muromegalovirus / Q000235:genetics / Q000302:isolation & purification / Q000502:physiology*; D012367:RNA, Viral / Q000235:genetics / Q000378:metabolism; D012160:Retina / Q000821:virology*; D015534:Trans-Activators / Q000378:metabolism; D014158:Transcription, Genetic; D014759:Viral Envelope Proteins / Q000378:metabolism; D010948:Viral Plaque Assay; D014775:Virus Activation; D017735:Virus Latency; D014779:Virus Replication
D004279:DNA, Viral; C094775:IE-1 protein, murine cytomegalovirus; D017874:Immediate-Early Proteins; D012367:RNA, Viral; D015534:Trans-Activators; D014759:Viral Envelope Proteins; C071440:glycoprotein H, Cytomegalovirus; C499358:glycoprotein H, Human cytomegalovirus; D003520:Cyclophosphamide